Cargando…
Human monoclonal antibodies and monoclonal antibody multispecificity.
The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents. They are also generally of the IgM isotyp...
Autores principales: | Campbell, A. M., Whitford, P., Leake, R. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002384/ https://www.ncbi.nlm.nih.gov/pubmed/3325093 |
Ejemplares similares
-
Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
por: Valente, Delphine, et al.
Publicado: (2020) -
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
por: Clarke, Starlynn C., et al.
Publicado: (2019) -
Next generation Fc scaffold for multispecific antibodies
por: Estes, Bram, et al.
Publicado: (2021) -
Multispecific Antibodies: DNA‐Mediated Assembly of Multispecific Antibodies for T Cell Engaging and Tumor Killing (Adv. Sci. 2/2020)
por: Pan, Liqiang, et al.
Publicado: (2020) -
Toward Drug-Like Multispecific Antibodies by Design
por: Sawant, Manali S., et al.
Publicado: (2020)